ArticleJCO precision oncology2026

Complete Response to Immune Checkpoint Inhibitor-Based Combination Therapy in PD-L1-High, Tumor Mutational Burden-Low Ovarian Sarcomatoid Squamous Cell Carcinoma.

Wan-Ting Hung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.